Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension.
Schrier
R W
RW
Estacio
R O
RO
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004656:Enalapril / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006333:Heart Failure / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology*; D015737:Nisoldipine / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D015737:Nisoldipine; D004656:Enalapril